Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > FY2020 Drug Pricing Reform
FY2020 Drug Pricing Reform
-
Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
-
Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
-
Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
-
Chuikyo Wary about Further Reduction in Generic Entry Prices
October 10, 2019
-
Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
-
Chuikyo Supports Earlier Price Cuts for Certain Off-Patent Brand-Name Drugs
September 26, 2019
-
Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
-
Chuikyo Agrees on Need to Look at More Examples to Craft Pricing Models for Cell & Gene Therapies
September 12, 2019
-
Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
September 12, 2019
-
Chuikyo Members Open to Post-Launch Premiums for Add’l Indications, but Call for Careful Application
September 12, 2019
-
9 Topics Presented towards 2020 Pricing Reform; Industry Hearing Slated for November-December: Chuikyo
September 12, 2019
-
Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
-
Chuikyo to Revisit Generic Price-Band Rule
July 26, 2019
-
Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
-
Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
-
Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
-
Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
-
Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
-
3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
-
Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…